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BACKGROUND AND PURPOSE
Frankincense, the gum resin derived from Boswellia species, showed anti-inflammatory efficacy in animal models and in pilot
clinical studies. Boswellic acids (BAs) are assumed to be responsible for these effects but their anti-inflammatory efficacy in vivo
and their molecular modes of action are incompletely understood.
EXPERIMENTAL APPROACH
A protein fishing approach using immobilized BA and surface plasmon resonance (SPR) spectroscopy were used to reveal
microsomal prostaglandin E2 synthase-1 (mPGES1) as a BA-interacting protein. Cell-free and cell-based assays were applied to
confirm the functional interference of BAs with mPGES1. Carrageenan-induced mouse paw oedema and rat pleurisy models
were utilized to demonstrate the efficacy of defined BAs in vivo.
KEY RESULTS
Human mPGES1 from A549 cells or in vitro-translated human enzyme selectively bound to BA affinity matrices and SPR
spectroscopy confirmed these interactions. BAs reversibly suppressed the transformation of prostaglandin (PG)H2 to PGE2
mediated by mPGES1 (IC50 = 3–10 mM). Also, in intact A549 cells, BAs selectively inhibited PGE2 generation and, in human
whole blood, b-BA reduced lipopolysaccharide-induced PGE2 biosynthesis without affecting formation of the COX-derived
metabolites 6-keto PGF1a and thromboxane B2. Intraperitoneal or oral administration of b-BA (1 mg·kg-1) suppressed rat
pleurisy, accompanied by impaired levels of PGE2 and b-BA (1 mg·kg-1, given i.p.) also reduced mouse paw oedema, both
induced by carrageenan.
CONCLUSIONS AND IMPLICATIONS
Suppression of PGE2 formation by BAs via interference with mPGES1 contribute to the anti-inflammatory effectiveness of BAs
and of frankincense, and may constitute a biochemical basis for their anti-inflammatory properties.
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Introduction
Extracts of the gum resins from Boswellia species
(frankincense) are commonly used in folk medicine
to treat various inflammatory disorders. The penta-
cyclic triterpenes boswellic acids (BAs; Figure 1) are
assumed to be the pharmacological active principles
of frankincense extracts, and based on data obtained
from experiments using cellular and animal models
(Poeckel and Werz, 2006), there is accumulating evi-
dence for anti-inflammatory and anti-tumorigenic
effects of BAs. Pilot clinical studies have suggested
some efficacy of frankincense preparations in the
treatment of osteoarthritis (OA), rheumatoid arthri-
tis (RA), inflammatory bowel diseases, asthma and
cancer (see Ammon, 2006; Poeckel and Werz, 2006).
Molecular mechanisms responsible for these thera-
peutics effects have been mainly attributed to the
interference of 3-O-acetyl-11-keto-b-BA (AKBA) with
signalling pathways including the nuclear factor-kB
route (Syrovets et al., 2005), mitogen-activated
protein kinase pathway and Ca2+ signalling (Poeckel
et al., 2006a) as well as targeting human leukocyte
elastase (HLE) (Safayhi et al., 1997), 5-lipoxygenase
(5-LOX) (Safayhi et al., 1992), platelet-type 12-
lipoxygenase (12S-LOX) (Poeckel et al., 2006b) and
COX-1 (Siemoneit et al., 2008). However, in vivo
studies confirming the pharmacological relevance of
these proposed target interactions are still missing,
and the efficacy of defined BAs in in vivo models of
inflammation remains to be assessed. Recently, we
showed that the serine protease cathepsin G is a
high affinity and pharmacologically relevant target
of BAs (Tausch et al., 2009).
Prostaglandins (PGs) are important lipid media-
tors derived from arachidonic acid (AA) that control
not only numerous physiological events such as
blood pressure, blood clotting and sleep, but also
inflammation (Funk, 2001). PGE2 is a key player in
pyresis, pain and inflammatory responses (Smith,
Figure 1
Chemical structures of boswellic acids (BAs) and a-amyrin. 3-O-Acetyl-b-boswellic acid (Ab-BA); 3-O-acetyl-11-keto-b-boswellic acid (AKBA);
b-boswellic acid (b-BA); 11-keto-b-boswellic acid (KBA); 3-O-oxaloyl-11-b-keto-boswellic acid (ox-KBA).
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1989), and the beneficial therapeutic effects of non-
steroidal anti-inflammatory drugs (NSAIDs) are
essentially attributed to the suppression of PGE2
(Funk, 2001). The biosynthetic pathway to PGE2
includes the release of AA from membrane phos-
pholipids by phospholipases A2 followed by conver-
sion via COX-1 and -2 to PGH2 and its subsequent
isomerization by PGE2 synthases (PGES). mPGES1 is
induced by pro-inflammatory stimuli such as
interleukin-1b (IL-1b) or lipopolysaccharide (LPS),
and receives PGH2 preferentially from COX-2
(Murakami et al., 2002). Thus, inflammation, pain,
fever and different types of cancer are closely linked
to the increased PGE2 formation originating from
up-regulated mPGES1 (Samuelsson et al., 2007).
Data from studies using mPGES1-deficient mice
indicate that suppression of mPGES1 may provide
an efficient pharmacological approach for the treat-
ment of inflammatory diseases (Trebino et al., 2003),
avoiding effects on the formation of physiologically
important and homeostatic PGs.
Here, we have demonstrated that BAs were direct
inhibitors of mPGES1, and particularly b-BA (the
most abundant BA in frankincense) was highly effec-
tive in vitro and in vivo. Moreover, we analysed and
compared for the first time the anti-inflammatory
efficacy of the four major b-configured BAs in vivo. As
pathophysiological PGE2 formation is mainly related
to mPGES1 (Samuelsson et al., 2007), our findings
may provide amolecularmechanism contributing to
the anti-inflammatory efficacy of BAs or frankin-
cense preparations.
Methods
Animals
All animal care and experimental procedures com-
plied with Italian regulations on the protection of
animals used for experimental and other scientific
purpose (Ministerial Decree 116192), and with the
European Economic Community regulations (Offi-
cial Journal of E.C. L 358/1 12/18/1986). Male adult
CD1 mice (25–35 g, Harlan, Milan, Italy) and Wistar
Han rats (200–220 g, Harlan) were housed in a con-
trolled environment and provided with standard
rodent chow and water.
Cells and cell viability assay
A549 cells were cultured as described (Koeberle
et al., 2008) and cell viability was measured using
the colorimetric MTT dye reduction assay in a
96-well format using a multi-well scanning spectro-
photometer (Victor3 plate reader, PerkinElmer,
Rodgau-Juegesheim, Germany) as recently reported
(Koeberle et al., 2008). Neither a-amyrin nor any of
the five BAs (30 mM each) significantly reduced cell
viability within 5 h, compared with the effects of
dimethyl sulphoxide (DMSO) as vehicle (data not
shown), excluding possible acute cytotoxic effects of
the compounds in the cellular assays.
Cell-free expression of human mPGES1
Human mPGES1 was obtained by the continuous-
exchange cell-free expression system according to
Schwarz et al. (2007). This system comprises a reac-
tion mixture that contains Escherichia coli S30
extract (derived from the A19 strain), T7 poly-
merase, tRNAs, pyruvate kinase and the template
DNA for human mPGES1 (cloned in the pBH4
vector derived from pET19b, Novagen, Gibbstown,
NJ, USA). The reaction mixture was dialysed against
the feeding mixture that supplies amino acids,
energy equivalents acetyl phosphate, and phospho-
enol pyruvate as well as nucleotides. Reactions are
incubated at 30°C for up to 20 h. Protein synthesis
takes place in the reaction mixture and up to 1.5 mg
of mPGES1 per mL are obtained in the precipitate.
mPGES1 was resuspended in 50 mM potassium
phosphate buffer pH 7.4, 1 mM GSH, 10% glycerol
and 2% (w/v) LysoFos12 choline (Anatrace,
Maumee, OH, USA) for 2 h at 30°C, and insoluble
parts were removed by centrifugation (10 000¥ g
10 min, 10°C).
Protein pull-down assays using
immobilized BAs
For immobilization of BAs, b-BA or KBA were linked
to EAH Sepharose 4B beads via the C3-OH group
using glutaric acid as linker as described previously
(Poeckel et al., 2006b). For protein pull-down experi-
ments, 1 ¥ 107 A549 cells were lysed in 375 mL lysis
buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 2 mM phenylmethane-
sulfonyl fluoride, 10 mg·mL-1 leupeptin and
120 mg·mL-1 soybean trypsin inhibitor). After soni-
fication (3 ¥ 8 s) and centrifugation (12 000¥ g,
10 min, 4°C), 125 mL of the Sepharose slurries (50%,
v/v) were added to the lysates and incubated at 4°C
overnight, with continuous rotation. For pull-down
experiments with isolated mPGES1, 200 ng of the
purified enzyme was diluted into 500 mL lysis buffer
containing 1000-fold excess of E. coli (BL21 strain)
protein, and 100 mL of the Sepharose slurries (50%,
v/v) were added. Beads were extensively washed
three times with 10 volumes of binding buffer
(HEPES pH 7.4, 200 mM NaCl, 1 mM EDTA) and
precipitated proteins were denatured by the addi-
tion of sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) sample loading buffer
(20 mM Tris-HCl, pH 8, 2 mM EDTA, 5% (m/v)
SDS, 10% b-mercaptoethanol). After boiling (95°C,
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6 min), proteins were separated by SDS-PAGE and
analysed by Western blotting, using specific anti-
bodies against COX-2 (Biomol Intern., Hamburg,
Germany) and mPGES1 (Cayman Chemical, Ann
Arbor, MI, USA). Ponceau S-staining of the mem-
branes after blotting assured equal protein loading
of bound proteins to the beads.
Surface plasmon resonance spectroscopy
A BIAcore X device (GE Healthcare Bio-Sciences,
Freiburg, Germany) was used. In vitro-translated
mPGES1 (100 mg·mL-1) in 10 mM Na-acetate pH 6.0
was coupled to a carboxymethylated dextran surface
(CM-5 chip, GE Healthcare) using standard amine
coupling procedure according to the manufacturer’s
instructions. Flow cell 1 on the chip was not altered
(reference) whereas on flow cell 2, mPGES1
(236 fmol·mm-2) was immobilized corresponding to
4700 resonance units (RU) and equilibrated by a
continuous flow of assay buffer (10 mM HEPES,
150 mMNaCl, 0.01% surfactant P20, and 1%DMSO,
pH 7.4) The stock solution of 3-O-oxaloyl-KBA (in
DMSO) was diluted into assay buffer. Measurements
were performed at 25°C and at a flow rate of
30 mL·min-1. After recording association, the liquid
phase was replaced by assay buffer, and the dissocia-
tion was monitored. The binding profiles were
obtained after subtracting the response signal of the
untreated reference cell 1, and sensograms were pro-
cessed by using automatic correction for non-specific
bulk refractive index effects using BIAEVALUATION
Version 3.1 software (GE Healthcare Bio-Sciences).
To obtain dissociation constants from the equi-
librium binding data, two different fitting models
were adopted. First, the change in the equilibrium
amount of compound bound as a function of the
concentration of compound was fitted to the equa-
tion (Eqn 1) for a simple 1:1 binding model:
R R compound K compoundeq max D= × [ ] + [ ]( )( (1)
where Req is the equilibrium response, Rmax is the
maximum response and KD is the dissociation con-
stant. A Scatchard analysis was also used to deter-
mine KD (represented by the negative reciprocal of
the slope). Analysis employing the BIAEVALUA-
TION software version 3.1 was performed to
determine kinetics. The integrated rate equation
describing a 1:1 Langmuir interaction was fitted
simultaneously to the entire concentration range for
3-O-oxaloyl-KBA. This fit yielded the association
rate ka, the dissociation rate kd and the dissociation
constant KD (Roden and Myszka, 1996; Karlsson and
Falt, 1997). The quality of the fit was determined by
the c2-values as well as the magnitude and distribu-
tion of the residuals.
Stimulation of A549 cells and isolation
of microsomes
Preparation of A549 cells was performed as
described (Koeberle et al., 2009). In brief, cells were
incubated for 16 h at 37°C and 5% CO2, and after
changing the medium, mPGES1 expression was
induced by IL-1b (1 ng·mL-1). After 72 h, cells were
frozen in liquid nitrogen, ice-cold homogenization
buffer (0.1 M potassium phosphate buffer pH 7.4,
1 mM phenylmethanesulfonyl fluoride, 60 mg·mL-1
soybean trypsin inhibitor, 1 mg·mL-1 leupeptin,
2.5 mM GSH and 250 mM sucrose) was added, and
after 15 min, cells were resuspended and sonicated
on ice (3 ¥ 20 s). The homogenate was subjected to
differential centrifugation at 10 000¥ g for 10 min
and at 174 000¥ g for 1 h at 4°C. The pellet (microso-
mal fraction) was resuspended in 1 mL homogeni-
zation buffer and the protein concentration was
determined by the Coomassie protein assay.
Determination of PGES1 activity in
microsomes of A549 cells
Microsomal membranes of A549 cells were diluted
in potassium phosphate buffer (0.1 M, pH 7.4) con-
taining 2.5 mM GSH (100 mL total volume), and
PGE2 formation was initiated by the addition of
PGH2 (20 mM, final concentration). After 1 min at
4°C, the reaction was terminated with 100 mL of
stop solution (40 mM FeCl2, 80 mM citric acid and
10 mM of 11b-PGE2); PGE2 was separated by solid
phase extraction and analysed by reversed phase-
high performance liquid chromatography (RP-
HPLC) as described (Koeberle et al., 2009).
Determination of PGE2 and 6-keto PGF1a
formation in intact A549 cells
The expression of mPGES1 in A549 cells was
induced as described previously. After trypsiniza-
tion, cells were washed twice with phosphate-
buffered saline (PBS), resuspended in PBS
(4 ¥ 106 mL-1) containing CaCl2 (1 mM) and pre-
incubated with the indicated compounds at 37°C
for 10 min. Prostanoid formation was started by the
addition of ionophore A23187 (2.5 mM), AA (1 mM)
and [3H]AA (18.4 kBq). The reaction was stopped
after 15 min at 37°C, and the samples were put on
ice. For quantification of radiolabelled PGE2,
samples were extracted, fractionated by HPLC and
then analysed by liquid scintillation counting (Koe-
berle et al., 2008). 6-Keto PGF1a was determined by
High Sensitivity EIA Kits (Assay Designs, Ann Arbor,
MI, USA) according to the manufacturer’s protocols.
Determination of prostanoid formation in
human whole blood
Human venous blood from healthy adult donors,
who had not received any medication for at least
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2 weeks (Blood Center, University Hospital Tuebin-
gen, Germany), was freshly withdrawn and col-
lected in monovettes containing 16 IE heparin mL-1
(Sarstedt, Nümbrecht, Germany). For determination
of PGE2 and 6-keto PGF1a, aliquots of whole blood
(0.8 mL) were mixed with CV4151 (1 mM) and with
aspirin (50 mM). For determination of TXB2, aliquots
of whole blood (0.5 mL) were used without the addi-
tion of CV4151. A total volume of 1 mL was
adjusted with sample buffer (10 mM potassium
phosphate buffer pH 7.4, 3 mM KCl, 140 mM NaCl
and 6 mM D-glucose). After pre-incubation with the
indicated compounds for 5 min at room tempera-
ture, the samples were stimulated with LPS
(10 mg·mL-1) for 5 h at 37°C. Prostanoid formation
was stopped on ice, the samples were centrifuged
(2300¥ g, 10 min, 4°C), and 6-keto PGF1a and TXB2
were quantified in the supernatant using High Sen-
sitivity EIA Kits (Assay Designs), according to the
manufacturer’s protocols. PGE2 was determined as
described (Koeberle et al., 2008). In brief, the super-
natant was acidified with citric acid (30 mL, 2 M),
and after centrifugation (2300¥ g, 10 min, 4°C),
solid phase extraction and RP-HPLC, analysis of
PGE2 was performed to isolate PGE2. The PGE2 peak
(3 mL), identified by co-elution with the authentic
standard, was collected, and acetonitrile was
removed under a nitrogen stream. The pH was
adjusted to 7.2 by the addition of 10 ¥ PBS buffer pH
7.2 (230 mL) before PGE2 contents were quantified
using a PGE2 High Sensitivity EIA Kit (Assay Designs)
according to the manufacturer’s protocol.
For determination of the COX product 12(S)-
hydroxy-5-cis-8,10-trans-heptadecatrienoic acid (12-
HHT), freshly drawn human blood (2 mL) was
pre-incubated with the indicated compounds at
37°C for 10 min, and 30 mM Ca2+ ionophore A23187
was added. After 10 min, the reaction was stopped
on ice, and the samples were centrifuged (600¥ g,
10 min, 4°C). Aliquots of the resulting plasma
(500 mL) were then mixed with 2 mL of methanol,
and 200 ng prostaglandin B1 was added as internal
standard. The samples were cooled to -20°C for 2 h
and centrifuged again (600¥ g, 15 min, 4°C). The
supernatants were collected and diluted with 2.5 mL
PBS and 75 mL HCl 1N, and formed 12-HHT was
extracted and analysed by HPLC as described
(Siemoneit et al., 2008).
Carrageenan-induced paw oedema
Mice were divided into groups (n = 10 for each
group) and lightly anaesthetized with enflurane
(4%) mixed with O2, 0.5 L·min-1, and N2O,
0.5 L·min-1. Each group of animals received sub-
plantar administration of saline (0.05 mL) or
l-carrageenan type IV (1% w/v) (0.05 mL) in saline.
The paw was marked in order to immerse it to the
same extent in the measurement chamber. The
volume was measured by using a hydroplethys-
mometer, specially modified for small volumes (Ugo
Basile, Milan, Italy) immediately before subplantar
injection and 2, 4 and 6 h thereafter. The assessment
of paw volume was performed always under double
blind conditions and by the same operator. The
increase in paw volume was calculated by subtract-
ing the initial paw volume (basal) to the paw
volume measured at each time point.
Carrageenan-induced pleurisy
Rats were anaesthetized with enflurane (4%) mixed
with O2, 0.5 L·min-1, N2O, 0.5 L·min-1, and submit-
ted to a skin incision at the level of the left sixth
intercostal space. The underlying muscle was dis-
sected, and saline (0.2 mL) or l-carrageenan type IV
(1% w/v) (0.2 mL) was injected into the pleural
cavity. The skin incision was closed with a suture,
and the animals were allowed to recover. At 4 h after
the injection of l-carrageenan, the animals were
killed by inhalation of CO2. The chest was carefully
opened, and the pleural cavity was rinsed with 2 mL
saline solution containing heparin (5 U·mL-1). The
exudate and washing solution were removed by
aspiration, and the total volume was measured
using an adjustable-volume pipette (P1000, range
volume 1000–200 mL or P200, range volume 200–
30 mL). Any exudate that was contaminated with
blood was discarded. The amount of exudate was
calculated by subtracting the volume injected
(2 mL) from the total volume recovered. Leukocytes
in the exudate were resuspended in PBS and
counted with an optical light microscope in a Burk-
er’s chamber after vital staining with Trypan blue.
The amounts of PGE2 and 6-keto PGF1a in the
supernatant of centrifuged exudate (800¥ g, 10 min)
were assayed by radioimmunoassay (PGE2) and EIA
(6-keto PGF1a), respectively (Cayman Chemical),
according to the manufacturer’s protocol. The
results are expressed as ng per rat and represent the
mean  SE of 10 rats.
Experimental design of animal experiments
For i.p. administration, the test compounds were
dissolved in DMSO and diluted with saline, achiev-
ing a final DMSO concentration of 2 or 4%. For oral
administration, the compounds were dissolved in
water containing 0.5% (w/v) carboxymethylcellu-
lose, 10% Tween-20 (v/v), and 1% sesame oil (v/v).
For carrageenan-induced paw oedema in the
treated group of animals, b-BA (0.25 and 1 mg·kg-1)
or indomethacin (5 mg·kg-1, reference compound)
were given i.p. 30 min before carrageenan. The
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vehicle-treated group of mice received DMSO 2%
(i.p.).
For carrageenan-induced pleurisy in the treated
group of animals, the BAs (1 mg·kg-1, each) and
indomethacin (5 mg·kg-1, reference compound)
were given either i.p. or p.o. 30 min before carrag-
eenan. The vehicle-treated group of rats received
DMSO 4% (i.p.) or water containing 0.5% CMC,
10% Tween-20 and 1% sesame oil (p.o.). DMSO (4%,
i.p.) itself did not affect exudate volume as com-
pared with saline (0.30  0.071 and 0.34  0.02 mL
respectively).
Data analysis
Data are expressed as mean  SE. The program
Graphpad Instat (Graphpad Software Inc., San
Diego, CA, USA) was used for statistical comparisons
of the data by one-way analyses of variance for inde-
pendent or correlated samples followed by Tukey
HSD post hoc tests. Where appropriate, Student’s
t-test for paired and correlated samples was applied.
A P value of <0.05 (*) was considered significant. IC50
values of compounds are approximations deter-
mined by graphical analysis (linear interpolation
between the points between 50% activity).
Materials
BAs were prepared as previously described (Jauch
and Bergmann, 2003). All BAs and synthetic deriva-
tives were at least 95% pure. Structures were con-
firmed by 1H-nuclear magnetic resonance (NMR)
spectroscopy, 13C-NMR spectroscopy, H,H-correlated
spectroscopy (COSY), heteronuclear multiple
quantum coherence (HMQC), heteronuclear mul-
tiple bond correlation, HMQC-COSY, and nuclear
Overhauser and exchange spectroscopy as well as
electrospray ionization mass spectrometry in the
negative mode. a-Amyrin was from Extrasynthèse
(Genay, France); EAH-Sepharose 4B was from GE
Healthcare Bio-Sciences (Freiburg, Germany);
thromboxane synthase inhibitor CV4151 was a gift
by Dr Stefan Laufer (Tuebingen, Germany); DMEM/
High glucose (4.5 g·L-1) medium, penicillin, strepto-
mycin, trypsin/EDTA solution, were from PAA
(Coelbe, Germany); PGH2 was from Larodan
(Malmö, Sweden); 11b-PGE2, MK-886, [5, 6, 8, 9, 11,
12, 14, 15-3H] AA ([3H]AA), were from BioTrend
Chemicals GmbH (Cologne, Germany); Ultima
GoldTM XR was from Perkin Elmer (Boston, MA,
USA); l-carrageenan type IV isolated from Gigartina
aciculaire and Gigartina pistillata was from Sigma-
Aldrich (Milan, Italy); [3H-PGE2], PerkinElmer Life
Sciences (Milan, Italy); PGE2 antibody, Sigma-
Aldrich. AA, LPS, fetal calf serum and all other
chemicals were obtained from Sigma-Aldrich
(Deisenhofen, Germany) unless stated otherwise.
Nomenclature for the receptors and molecular
targets studied here follows Alexander et al. (2009).
Results
Identification of mPGES1 as a
BA-binding protein
A target fishing approach using immobilized BAs
(Poeckel et al., 2006b) was applied in order to inves-
tigate whether or not BAs interact with mPGES1.
Lysates of IL-1b-treated A549 cells, expressing
mPGES1 (Jakobsson et al., 1999), were incubated
with resins composed of b-BA or KBA, linked via the
C3-OH moiety to glutaric acid and coupled to EAH
Sepharose 4B beads yielding b-BA-Seph or KBA-Seph
respectively. EAH Sepharose 4B beads without
ligand (Seph) were used as the negative control.
Beads were extensively washed and the bound pro-
teins were detached by the addition of SDS-PAGE
sample loading buffer followed by separation by
SDS-PAGE and Western blot analysis, using specific
antibodies against mPGES1 and COX-2. Substantial
amounts of mPGES1 were bound to BA-Seph beads
but hardly any was bound to Seph beads without
ligand (Figure 2A). In contrast, COX-2 was not
detected in these precipitated proteins. Further-
more, in vitro-translated mPGES1 (200 ng purified
Figure 2
Boswellic acids (BAs) bind to microsomal prostaglandin E2 synthase 1
(mPGES1). (A) Supernatants of A549 cell lysates were incubated with
b-BA-Seph, KBA-Seph or with Seph, as indicated. (B) Purified, in
vitro-translated mPGES1 (200 ng) was incubated with b-BA-Seph,
KBA-Seph or Seph beads. Precipitated proteins were separated by
SDS-PAGE, and visualized by Western blotting, using specific anti-
bodies against mPGES1 (A,B) or COX-2 (A). An aliquot of the super-
natant was used as positive control. Similar results were obtained in
three additional experiments. KBA, 11-keto-b-boswellic acid; SDS-
PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis.
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protein) in the presence of 1000-fold excess of E. coli
protein was precipitated by both KBA-Seph and
b-BA-Seph, but was minimally precipitated by Seph
beads (Figure 2B).
To characterize the interaction of BAs with
mPGES1 in more detail, surface plasmon resonance
(SPR) spectroscopy studies were carried out. The
progress of interaction, binding of analyte (associa-
tion) and dissociation from the immobilized
mPGES1 was monitored as a sensogram, expressing
changes in binding responses as RU. Unfortunately,
no consistent binding patterns were obtained using
naturally occurring BAs as analytes, presumably
due to their high lipophilicity leading to
concentration-dependent aggregation and super-
stoichiometric binding behaviour (Giannetti et al.,
2008). Neither the addition of bovine serum
albumin as carrier protein nor the variation of
commercial assay buffers (with or without deter-
gent) or changes in temperature improved the
quality of the recorded sensograms. Hence, we used
the more hydrophilic synthetic derivate 3-O-
oxaloyl-KBA (10 mM) to obtain more valuable
and reproducible sensograms, which indicated
specific reversible binding to mPGES1 (Figure 3A).
a-Amyrin (a pentacyclic triterpene which lacks the
C4-COOH moiety of BAs; Figure 1) failed to bind
mPGES1 up to concentrations of 30 mM (Figure 3A).
In order to determine equilibrium-binding con-
stants, 3-O-oxaloyl-KBA was analysed at concentra-
tions ranging from 0.5 to 25 mM. The equilibrium
response (Req) was calculated, and fitting the data to
the 1:1 binding model (Eqn. 1) and Scatchard plot
analysis yielded KD values of 13 and 5.2 mM respec-
tively (Figure 3B).
Kinetic data were estimated using BIAEVALUA-
TION 3.1 software. Assuming the simple relation-
ship ka/kd = KD for 3-O-oxaloyl-KBA, a KD value of
23 mM was calculated that essentially matches the
KD obtained from the equilibrium binding data
(Figure 3C). Nevertheless, these kinetic parameters
should be regarded as rough determinations rather
than absolute values. Together, these data support a
direct physical interaction between BAs and
mPGES1.
BAs inhibit the catalytic activity of mPGES1
in a cell-free assay
Next, we investigated whether BAs may affect the
catalytic activity of mPGES1. Isolated microsomes of
IL-1b-treated A549 cells were pre-incubated with
BAs, and PGE2 formation was induced by the addi-
tion of 20 mM PGH2. The mPGES1 inhibitor MK-886
was used as reference drug (Claveau et al., 2003;
Koeberle et al., 2008) and blocked PGE2 formation
with an IC50 = 2 mM (not shown). AKBA, b-BA and
KBA concentration dependently suppressed PGE2
formation with IC50 values of 3, 5, and 10 mM
respectively. As previously observed for other
mPGES1 inhibitors (Koeberle et al., 2008; Koeberle
and Werz, 2009), about 20–30% activity still
remained even at high concentrations of BAs
(100 mM, Figure 4A) or of MK-886 (30 mM, not
shown), suggesting mPGES1-independent basal
formation of PGE2. The synthetic derivative
3-O-oxaloyl-KBA suppressed PGE2 formation
(IC50 = 5 mM, not shown), which is in good agree-
ment with the SPR data. Ab-BA was less potent
(IC50  30 mM) and a-amyrin was entirely inactive
up to 100 mM (data not shown).
To assess whether the inhibition of mPGES1 by
BAs occurs in a reversible fashion, washout experi-
ments were performed. Microsomal preparations of
A549 cells were pre-incubated with BAs (10 mM,
each), and MK-886 (3 mM) served as a control for a
reversible mPGES1 inhibitor (Koeberle et al., 2008).
Because all four BAs should act by a common mode,
only the most active representatives (i.e. AKBA and
b-BA) were tested. MK-886 at 3 mM or BAs at 10 mM
efficiently blocked PGE2 formation (Figure 4B).
Upon 10-fold dilution, a significant loss of potency
was observed and the inhibition was comparable
with the effect of BAs at 1 mM or MK-886 at 0.3 mM.
Hence, BAs may inhibit mPGES1 in a reversible
manner, as did MK-886.
Effects of BAs on prostanoid biosynthesis in
intact cells
The treatment of A549 cells with IL-1b for 72 h
results in the co-expression of COX-2 and mPGES1
(Thoren and Jakobsson, 2000), whereas COX-1 is
essentially absent (Asano et al., 1996). We used this
model to assess whether BAs inhibit PGE2 formation
also in intact cells, and whether BAs selectively
inhibit COX-2-derived PGH2 transformation to
PGE2 without affecting the biosynthesis of other
COX-2-derived prostanoids (i.e. 6-keto PGF1a). The
formation of prostanoids was induced by the stimu-
lation of A549 cells with 2.5 mM A23187 plus 1 mM
AA and 3[H]AA (18.4 kBq). The use of A23187 and
exogenous AA to induce prostanoid formation
excludes effects of BAs on receptor-coupled signal
transduction and/or on endogenous substrate
supply for COX-2. In agreement with the effects in
the cell-free mPGES1 activity assay, AKBA, KBA and
b-BA (30 mM, each) significantly inhibited PGE2 syn-
thesis to the same extent as MK-886 (30 mM),
whereas Ab-BA or a-amyrin were barely or not active
(Figure 5A). More detailed analysis showed that
AKBA, KBA and b-BA suppressed PGE2 synthesis in a
concentration-dependent manner (IC50 approxi-
mately 20–30 mM, Figure 5B). Nevertheless, the
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suppression of PGE2 formation by BAs was not
complete and 30 mM MK-886 also caused only
47% inhibition (Figure 5A). Importantly, the con-
comitant generation of 6-keto PGF1a was unaffected
by all BAs, a-amyrin and by MK-886 (Figure 5A),
whereas the COX-2 inhibitor celecoxib (5 mM)
blocked the formation of both PGE2 and 6-keto
PGF1a to the same extent, as expected. Also, cele-
coxib was much more efficient in the suppression of
PGE2 formation, compared with BAs or MK-886
(Figure 5A).
Effects of BAs on prostanoid formation in
human whole blood
In order to estimate the efficacy of BAs to interfere
with (COX-2/mPGES1-derived) PGE2 formation in a
more complex biological test system, human whole
blood assays were performed. Heparinized blood
was pre-incubated with BAs for 10 min, prior to
stimulation with LPS (10 mg·mL-1) for 5 h (Koeberle
et al., 2008). b-BA significantly reduced PGE2 synthe-
sis (46% inhibition) at 10 mM comparable with
MK-886 at 30 mM (45% inhibition), whereas the
Figure 3
Analysis of the binding of boswellic acids to microsomal prostaglandin E2 synthase 1 (mPGES1) by surface plasmon resonance spectroscopy. In
vitro-translated mPGES1 was coupled to a CM5 biosensor chip and 3-O-oxaloyl-KBA was used as analyte. Specific binding profiles were obtained
after subtracting the signal [response units (RU)] from the untreated control cell. (A) Binding of 3-O-oxaloyl-KBA (ox-KBA) and a-amyrin (10 mM
each) to mPGES1. (B) Binding curves for 3-O-oxaloyl-KBA. The equilibrium responses (Req) for 3-O-oxaloyl-KBA at different concentrations were
plotted versus the concentration of the compound. (C) Kinetic analysis of 3-O-oxaloyl-KBA-binding to mPGES1. Representative sensograms for the
injection of 0.5 mM up to 25 mM 3-O-oxaloyl-KBA are shown. A general analysis was applied to fit the data to a 1:1 binding model (bold lines),
and the quality of the fit is displayed by the plots of the residuals. Results are representative for at least three independent experiments. KBA,
11-keto-b-boswellic acid.
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Figure 4
Effects of boswellic acids (BAs) on the activity of microsomal prostaglandin E2 synthase 1 (mPGES1) in a cell-free assay. (A) Concentration-response
analysis. Microsomal preparations of IL-1b-stimulated A549 cells were pre-incubated with vehicle (DMSO) or BAs for 15 min at 4°C. PGH2 was
added and after 1 min, the reaction was stopped and PGE2 was analysed by RP-HPLC as described. The 100% value corresponds to
944  118 pmol PGE2 formed. (B) Reversibility of mPGES1 inhibition. Microsomal fractions of IL-1b-stimulated A549 cells were pre-incubated with
3 mM MK-886 or 10 mM BAs. An aliquot was diluted 10-fold to obtain an inhibitor concentration of 0.3 and 1 mM respectively. For comparison,
microsomal preparations were pre-incubated with 0.3 mM MK-886, 1 mM BA or with vehicle (veh, DMSO), and then, 20 mM PGH2 was added (no
dilution). After 1 min, PGE2 formation was analysed by RP-HPLC. Data are given as mean + SE, n = 3–4, ***P < 0.001 versus vehicle (DMSO)
control. DMSO, dimethyl sulphoxide; RP-HPLC, reversed phase-high performance liquid chromatography.
Figure 5
Effects of boswellic acids (BAs) on PGE2 and 6-keto PGF1a formation in intact A549 cells. IL-1b-treated A549 cells were pre-incubated (A) with
vehicle (veh, DMSO), BAs (30 mM each), a-amyrin (30 mM), MK-886 (30 mM) or celecoxib (cele, 5 mM) (B) with BAs at the indicated concen-
trations. After 10 min at 37°C, 2.5 mM A23187 plus 1 mM AA and [3H]AA (18.4 kBq) were added (or left untreated = unstim.) and after another
15 min, formed [3H]PGE2 was analysed as described in the Methods. 6-Keto PGF1a was analysed using High Sensitivity EIA Kits; the 100% value
corresponds to 87  11 pg 106 cells. Data are given as mean + SE, n = 3–5. ***P < 0.001 versus vehicle (DMSO) control. AA; arachidonic acid;
DMSO, dimethyl sulphoxide.
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other BAs and a-amyrin failed in this respect
(Figure 6A). Concentration-response experiments
revealed an IC50 value of 10 mM for b-BA (Figure 6B),
but even at high concentrations (100 mM), about
40% PGE2 still remained. Indomethacin (50 mM)
and celecoxib (20 mM) efficiently inhibited PGE2 for-
mation in whole blood. In contrast, the concomi-
tant formation of the COX-2-derived 6-keto PGF1a
(Figure 6C) or TXB2 (Figure 6D) was not affected by
b-BA or AKBA (and also not by Ab-BA or KBA, not
shown), implying that the suppressive effect on
PGE2 synthesis is not related to reduced generation
of the common precursor PGH2 (e.g. by inhibition
of PLA2 or COX), but instead is due to select inhibi-
tion of PGH2 transformation to PGE2. Indomethacin
and celecoxib efficiently suppressed the formation
of all three prostanoids as expected. Moreover, b-BA
(50 mM), in contrast to indomethacin, failed to
Figure 6
Effects of boswellic acids (BAs) on prostanoid biosynthesis in human whole blood. Heparinized human whole blood, treated with 1 mM CV4152
and 50 mM aspirin, was pre-incubated with (A) BAs and a-amyrin (10 mM, each) or vehicle (veh, DMSO) for 10 min at RT and then 10 mg·mL-1
LPS was added (or left untreated = unstim.). After 5 h at 37°C, PGE2 was separated by RP-HPLC and quantified by EIA. Controls: MK-886 (30 mM),
indomethacin (indo, 50 mM), and celecoxib (cele, 20 mM). (B) Concentration-response of b-BA. (C,D) 6-keto PGF1a and TXB2 formation. 6-Keto
PGF1a (C) was directly determined in blood plasma from samples above (see A) incubated with b-BA or AKBA (10 mM, each), indo (50 mM), cele
(20 mM) or veh (DMSO). Inhibition of TXB2 formation (D) was assessed in heparinized human whole blood without CV4152 and aspirin. Both
6-keto PGF1a and TXB2 were measured by EIA. The 100% values corresponds to 221.8  19.7 pg·mL-1 PGE2, 382.5  22.3 pg·mL-1 6-keto PGF1a,
and 37.9  4.4 ng·mL-1 TXB2 respectively. (E) 12-HHT formation. Heparinized human blood was pre-incubated with b-BA (50 mM), indo (20 mM)
or veh (DMSO) for 10 min, and A23187 (30 mM) was added (or left untreated = unstim.). After 10 min at 37°C, 12-HHT was analysed by HPLC.
The 100% value corresponds to 148.8  16.7 ng·mL-1 12-HHT. Data are given as mean + SE, n = 4–5; *P < 0.05; ***P < 0.001 versus vehicle (0.1%
DMSO) control. b-BA, b-boswellic acid; AKBA, 3-O-acetyl-11-keto-b-boswellic acid; DMSO, dimethyl sulphoxide; RP-HPLC, reversed phase-high
performance liquid chromatography.
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affect COX-1-mediated generation of 12-HHT in
whole blood stimulated with A23187 (Figure 6E).
Effects of BAs on carrageenan-induced rat
pleurisy and mouse paw oedema
Although the anti-inflammatory efficacy of unde-
fined mixtures of BAs in animal models are well
documented (Poeckel and Werz, 2006; Singh et al.,
2007), it is still unclear which of the BAs is respon-
sible for the beneficial actions in vivo. Therefore, we
assessed the effects of the four major b-configured
BAs in the well-recognized carrageenan-induced rat
pleurisy model. An injection of carrageenan into the
pleural cavity of rats (DMSO 4% group) elicited an
acute inflammatory response within 4 h character-
ized by the accumulation of exudate that contained
large numbers of inflammatory cells (Figure 7A).
b-BA (1 mg·kg-1) given i.p. 30 min prior to carrag-
eenan potently inhibited the inflammatory
response, as demonstrated by the significant attenu-
ation of exudate formation (75%) and cell infiltra-
tion (64%), being as effective as the reference drug
indomethacin (5 mg·kg-1, i.p.) (Figure 7A). Ab-BA
and KBA (1 mg·kg-1 i.p., each) were markedly
less efficient and AKBA (1 mg·kg-1 i.p.) caused no
significant effects. For b-BA, the PGE2 levels in the
Figure 7
Effects of boswellic acids (BAs) in animal models in vivo. (A) Carrageenan-induced pleurisy in rats. Thirty minutes before intrapleural injection of
carrageenan, rats (n = 10 for each experimental group) were treated i.p. with BAs (1 mg·kg-1 each), indomethacin (5 mg·kg-1) or vehicle (veh,
DMSO 4%). Exudate volume, PGE2 and 6-keto PGF1a levels as well as inflammatory cell accumulation in pleural cavity were assessed 4 h after
carrageenan injection. Data are expressed as mean  SE, n = 10. *P < 0.05; **P < 0.01; ***P < 0.01 versus vehicle; n.d. = not determined. (B)
Carrageenan-induced mouse paw oedema. Animals (n = 10 for each experimental group) were treated i.p. with 0.25 and 1 mg·kg-1 b-BA,
5 mg·kg-1 indomethacin (indo) or veh (2% DMSO) 30 min before carrageenan subplantar injection. Data are given as mean + SE, *P < 0.05;
**P < 0.01; ***P < 0.001 versus vehicle control. DMSO, dimethyl sulphoxide.
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exudates were reduced by 51%, whereas the amount
of 6-keto PGF1a was only slightly, and non-
significantly, reduced. The other BAs hardly reduced
PGE2 levels (<28%). Nevertheless, KBA and Ab-BA
significantly inhibited the generation of 6-keto
PGF1a by 35 and 40%. Indomethacin almost com-
pletely suppressed formation of PGE2 as well as
6-keto PGF1a (Figure 7A).
Next, b-BA was analysed for its anti-
inflammatory efficacy in vivo after oral administra-
tion. As shown in Table 1, b-BA (1 mg·kg-1) caused
potent inhibition of exudate formation and pre-
vented infiltration of inflammatory cells, along with
reduced levels of PGE2. The reference compound
indomethacin (5 mg·kg-1), given p.o., completely
prevented the formation of PGE2 associated with
strong inhibition of exudate formation and cell
infiltration (Table 1).
Finally, we explored the efficacy of b-BA in
carrageenan-induced paw oedema, another rodent
model of acute inflammation, to assess the patho-
physiological role of mPGES1 in inflammation in
vivo (Guay et al., 2004). The injection of carrageenan
into the mouse paw produced a marked increase of
paw volume, with a maximal effect after 4 h. Pre-
treatment (30 min) of mice with b-BA attenuated
the inflammatory response at 4 h (Figure 7B). Thus,
for mice treated (i.p.) with 0.25 and 1 mg·kg-1 of
b-BA, the peak of the response to carrageenan at 4 h
was reduced by 20 and 50% respectively.
Indomethacin (5 mg·kg-1) caused 57% inhibition of
the carrageenan response.
Discussion and conclusions
The modes of action and molecular targets of BAs
and frankincense preparations are still incompletely
understood. Most studies have focused on AKBA or
KBA as the pharmacologically active principles and
numerous targets (5-LOX, 12S-LOX, COX-1, HLE,
IkB kinases and topoisomerases) have been pro-
posed, but the interference with these targets in vivo
has been largely neglected and thus, the pharmaco-
logical relevance is still unclear. Recently, we pre-
sented the identification of cathepsin G as a
pharmacologically relevant target of all major BAs
(Tausch et al., 2009). PGE2 is a key player in inflam-
mation and pain, and mPGES1 is regarded as a
potential target for the development of anti-
inflammatory therapeutics (Samuelsson et al., 2007).
Here, we present mPGES1 as a molecular target of
BAs, and we provide evidence for a functional inter-
action of b-BA with mPGES1 in vivo which may
contribute to its anti-inflammatory effectiveness.
The mPGES-1 bound to immobilized b-BA and
KBA in a pull-down assay and SPR spectroscopy data
confirmed a direct interaction. Pull-down assays
using immobilized BAs were previously applied to
demonstrate a direct interference of BAs with
COX-1, 12S-LOX and cathepsin G (Poeckel et al.,
2006b; Siemoneit et al., 2008; Tausch et al., 2009),
supporting the suitability of this methodology for
target identification. The SPR-based ligand-analyte
studies revealed KD values of 5.2–23 mM for 3-O-
oxaloyl-KBA, and these values fit the IC50 (5 mM) of
3-O-oxaloyl-KBA in the mPGES1 cell-free assay, sug-
gesting specific binding to mPGES1 and hence a
direct relation between enzyme binding and inter-
ference with mPGES1 activity.
AKBA, KBA and b-BA at low micromolar concen-
trations inhibited mPGES1-mediated PGE2 forma-
tion in cell-free assays, and also concentration
dependently blocked PGE2 biosynthesis in intact
A549 cells. Previous studies showed that BAs
(up to 100 mM) hardly inhibited isolated COX-2
Table 1
Effect of b-BA on carrageenan-induced pleurisy in rats
Treatment Exudate volume (mL) Inflammatory cells ¥ 106 PGE2 (ng·rat-1)
Vehicle 0.19  0.020 47.1  3.0 2.15  0.20
b-BA 0.029  0.016*** 29.6  2.8*** 1.21  0.14**
1 mg·kg-1 85% 37% 44%
Indo 0 17.0  4.9** n.d.
5 mg·kg-1 100% 64% 100%
**P < 0.01; ***P < 0.001 versus vehicle.
Thirty minutes before intrapleural injection of carrageenan, rats (n = 11 for each experimental group) were treated per os with 1 mg·kg-1 b-BA,
5 mg·kg-1 indomethacin (indo) or vehicle (water containing 0.5% CMC, 10% Tween-20 and 1% sesame oil). Exudate volume and PGE2, as
well as inflammatory cell accumulation in the pleural cavity were assessed 4 h after carrageenan injection. Data are expressed as mean  SEM,
n = 11.
b-BA, b-boswellic acid; n.d., not detectable, under the limit of detection of the assay (0.0625 ng·mL-1).
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(Siemoneit et al., 2008) and all BAs (up to 30 mM)
failed to reduce the formation of the COX-2-derived
products 6-keto PGF1a and TXB2 in intact A549 cells
and in human whole blood. Therefore, we conclude
that impaired PGE2 biosynthesis is the result of the
selective inhibition of the transformation of PGH2
to PGE2 by interference of BAs with mPGES1, rather
than with COX-2 or other distal events (such as AA
release). In particular b-BA, the major BA present in
frankincense that reaches the highest plasma levels
(up to 10.1 mM) among the BAs in treated humans
(Buchele and Simmet, 2003; Tausch et al., 2009),
suppressed PGE2 formation in human whole blood,
again without significant reduction of 6-keto PGF1a
or TXB2 levels. Interference with COX-1 was
excluded as 12-HHT formation in whole blood was
unaffected by b-BA, although BAs (in particular
AKBA and KBA) may inhibit COX-1 in cell-free and
cell-based models at higher concentrations (Siemo-
neit et al., 2008).
b-BA at a dose of 1 mg·kg-1 given i.p. or p.o.
reduced the inflammatory reaction in two in vivo
models of acute inflammation, carrageenan-induced
mouse paw oedema and rat pleurisy, being about
as effective as 5 mg·kg-1 indomethacin. During
carrageenan-induced oedema formation, PGE2 levels
are significantly elevated (Harada et al., 1982;
Guay et al., 2004), and COX inhibitors prevent
the inflammatory response (Gemmell et al., 1979).
Results from studies using carrageenan-induced paw
oedema and i.p. application of undefined mixtures
of BAs concur with our data, although much higher
doses (e.g. 125 mg·kg-1) were used in those studies
(Singh et al., 2007). Whether or not BAs and related
triterpenes present in frankincense extracts syner-
gize or antagonize each other remains to be inves-
tigated. In the early phase of carrageenan-induced
pleurisy, PGE2 plays a central role (Kawamura et al.,
2000); and in fact, exudates from b-BA-treated rats
showed markedly lower PGE2 levels. Thus, lowering
PGE2 by inhibition of mPGES1 may contribute to
the anti-inflammatory properties of b-BA. However,
compared with indomethacin, b-BA was less potent
in reducing PGE2 levels, but still efficiently sup-
pressed exudate formation and infiltration of
inflammatory cells. It is possible that other anti-
inflammatory features of b-BA, such as inhibition of
cathepsin G (Tausch et al., 2009), may contribute to
the overall anti-inflammatory effects. The inhibi-
tion of cathepsin G may also explain the slight but
still significant reduction of oedema formation and
cell infiltration upon pretreatment with Ab-BA,
which was the least potent inhibitor of mPGES1 and
failed to suppress PGE2 formation in whole blood.
Similarly, interference with other pro-inflammatory
components, such as cytokines and transcription
factors (Syrovets et al., 2005; Kunnumakkara et al.,
2009), may suppress COX-2 induction, explaining
the reduced 6-keto PGF1a levels in the exudates of
KBA- and Ab-BA-treated rats.
Initially, the inhibition of 5-LOX activity and
formation of leukotrienes (LTs) by BAs was proposed
as an anti-inflammatory mechanism (Poeckel and
Werz, 2006). Thus, AKBA and KBA blocked 5-LOX
with IC50 values of 1.5–50 mM depending on the
experimental settings (Safayhi et al., 1992; Siemo-
neit et al., 2009). However, in whole blood assays,
AKBA and KBA failed to inhibit 5-LOX product syn-
thesis, and the LTB4 plasma levels of human healthy
volunteers treated with standard doses of frankin-
cense were not affected (Siemoneit et al., 2009).
Similarly, AKBA and KBA failed to suppress PGE2
formation in human whole blood and in rats,
despite significant inhibition of mPGES1 in the cell-
free assay. The failure of KBA and AKBA to suppress
LT and PGE2 formation in vivo could be related to
the marginal permeability of AKBA and moderate
absorption of KBA (Kruger et al., 2009), resulting in
poor bioavailability (Kruger et al., 2008) with fairly
low plasma concentrations (0.3 and <0.1 mM)
(Buchele and Simmet, 2003; Tausch et al., 2009).
The marked loss of activity of AKBA in whole blood
might be related to its strong plasma protein
binding (Siemoneit et al., 2009). Together, the
11-keto moiety may hamper the cellular and bio-
logical availability of respective BAs in a physiologi-
cal environment and thus compromise the overall
anti-inflammatory effectiveness of AKBA in vivo. In
contrast, b-BA (at 1 mg·kg-1) showed comparably
high efficacy in the pleurisy model after p.o. or i.p.
administration, suggesting clearly different and
better bioavailability of this BA.
Our data favour a role of b-BA as the most rel-
evant anti-inflammatory BA acting at least in part via
inhibition of PGE2 formation. Pilot clinical studies
indicated some therapeutic efficacy of frankincense,
mainly in OA and RA (Ammon, 2006; Sengupta
et al., 2008). Clinical studies using 5-LOX inhibitors
(i.e. zileuton) and studies on 5-LOX- or 5-LOX-
activating protein-deficient mice, exclude a promi-
nent role of LTs in OA or RA (Werz and Steinhilber,
2006). However, PGE2 is a key mediator accounting
for typical disease symptoms in OA and RA (Smith,
1989); and in patients suffering from RA or OA, a
pivotal role for mPGES1 has been demonstrated
(Westman et al., 2004; Li et al., 2005). Moreover, data
from animal arthritis models support the relevance
of mPGES1 to inflammatory joint diseases (Claveau
et al., 2003; Trebino et al., 2003; Guay et al., 2004).
Hence, the inhibition of PGE2 biosynthesis by
b-BA may contribute to the beneficial effects of
frankincense preparations observed in clinical
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studies and animal models of OA and RA (Ammon,
2006). Such speculations are favoured by the close
correlation between steady-state plasma levels of
b-BA (6.4–10.1 mM) in humans obtained after oral
administration of frankincense preparations [con-
taining 18.2% b-BA, 10.5% Ab-BA, 6.1% KBA and
3.7% AKBA (Sterk et al., 2004)] in clinical trials
(Buchele and Simmet, 2003; Tausch et al., 2009) and
the effective concentrations of b-BA (3 mM) to sup-
press PGE2 synthesis in human whole blood.
The mPGES1 inhibitors might be alternatives to
NSAIDs with reduced side effects (Koeberle and
Werz, 2009). Less gastric and cardiovascular compli-
cations were evident in mPGES1-deficient mice,
compared with COX-1- or COX-2-deficient mice or
mice treated with NSAIDs (Cheng et al., 2006; Wang
et al., 2006). In fact, the mPGES1 inhibitor MF63
relieved pyresis and inflammatory pain in animal
models, without NSAID-like gastric toxicity (Xu
et al., 2008). BAs showed gastric ulcer protective
effects in different experimental models (Singh
et al., 2008), and a 90-day placebo-controlled study
supports evidence for the safety of Boswellia serrata
extracts in OA patients (Sengupta et al., 2008).
In conclusion, we have shown that BAs directly
and functionally interfered with mPGES1. The for-
mation of PGE2 was selectively suppressed by b-BA
in cell-based assays and in pleural exudates in vivo,
and b-BA clearly exhibited anti-inflammatory effec-
tiveness in the carrageenan-induced mouse paw
oedema and rat pleurisy after i.p. or p.o. adminis-
tration of fairly low doses. As the effective concen-
trations of b-BA, under physiologically relevant
conditions, were in the range of b-BA levels in
plasma of humans treated with frankincense, an
interference with mPGES1 might represent a reason-
able molecular mechanism contributing to some of
the anti-inflammatory properties of frankincense
extracts and rationalize its therapeutic use.
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